Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Sites / University of California Los Angeles / Fishbein, Michael

Fishbein, Michael (M.D.)

Staff, University of California Los Angeles , 310-825-9731

Contact Information


To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Breast tissue array 0 0
The Early Detection Research Network: Biomarker Reference Laboratories 0 0
Early Detection of Urinary Bladder Cancer 0 0
Validation of Biomarkers for the Early Detection of Colorectal Adenocarcinoma (GLNE 010) 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Lung Reference Set A Application: Lee Goodglick/ Eleftherios Diamandis- UCLA/MSH (2009) 0 0
GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysplasia and Adenocarcinoma 0 0
Soluble Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM) 2 0
Validation of Serum Markers for the Early Detection of Hepatocellular Carcinoma 3 0


Publication Name PubMed ID Journal
Protein expression based multimarker analysis of breast cancer samples. 21651811 BMC Cancer
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. 21600232 Steroids
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. 18316555 Clin. Cancer Res.
Aromatase expression predicts survival in women with early-stage non small cell lung cancer. 17974992 Cancer Res.
Expression of transcription factor Yin Yang 1 in prostate cancer. 15942652 Int. J. Oncol.
Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. 15567174 Biochem. Biophys. Res. Commun.
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. 16949910 Hum. Pathol.
Direct electronic detection of prostate-specific antigen in serum. 17352433 Small
COX-2-dependent stabilization of survivin in non-small cell lung cancer. 14597555 FASEB J.
Prostate cancer cell phenotypes based on AGR2 and CD10 expression. 23348903 Mod. Pathol.
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. 19729831 Cancer Biomark
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. 19887480 Clin. Cancer Res.
Global levels of histone modifications predict prognosis in different cancers. 19349354 Am. J. Pathol.
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. 21689459 BMC Cancer
Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. 20710044 Cancer Res.
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. 17947468 Clin. Cancer Res.
Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. 22345575 Am. J. Physiol. Lung Cell Mol. Physiol.
Elevated MED28 expression predicts poor outcome in women with breast cancer. 20584319 BMC Cancer
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. 21504557 J Transl Med
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. 21511357 Lung Cancer
Higher levels of GATA3 predict better survival in women with breast cancer. 21078439 Hum. Pathol.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.


10833 Le Conte Avenue
University of California, Los Angeles

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

The 34th EDRN Steering Committee is from March 18-20, 2019 in Nashville TN.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.